OCUL (ocutx.com) Market Value to Book Value Ratio

Ocular Therapeutix Inc (OCUL) - corporate logo

Ocular Therapeutix develops ophthalmological drugs through institutional partnerships, optimizing the implementation of implants. The brand is valued by surgeons for creating safe hydrogel healing systems. This price chart on GURU.Markets, illustrating trading dynamics, shows quotes at 3.08. Future success depends on the speed of product time-to-market and overcoming competitive pressure within the sector.

Ocular Pharma (OCUL) - Market Value to Book Value from 07/04/2022 to 10/30/2026

Ocular Therapeutix Inc (OCUL) - metric breakdowns and financial figures

- market value and analyst target forecast:
Price Chart Ocular Therapeutix|OCUL - Price Target Chart
- business market valuation indicators:
Market Value Ocular Therapeutix Corp|OCUL - Full Business Value
- book capitalization data:
Book Value per Share Ocular Therapeutix|OCUL - Accounting Value of Company|Market Capitalization to Book Value Ratio ocutx.com|OCUL - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Equity Ocular Therapeutix|OCUL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ocular Therapeutix Corp|OCUL - Company Total Debt|Debts to Book Capitalization Ocular Therapeutix Corp|OCUL - Company Long-Term Debts|Company Current Liabilities Ocular Therapeutix|Quick Ratio ocutx.com
- earnings and valuation multiples indicators:
OCUL - Company Net Income
Basic company analysis:Ocular Therapeutix - OCUL
Manufactured product of Ocular Therapeutix Corp

This ratio compares the current market value of Ocular Therapeutix (OCUL) to its net assets, allowing investors to determine the extent to which the shares are overvalued relative to actual capital. By analyzing the trend of the market-to-book value ratio, one can assess the degree to which the market is willing to pay a premium for the company's highly skilled staff of biochemists and its innovative developments in the field of ophthalmological implants.

Competitor analysis

Alcon Inc. (ALC) - Market Value to Book Value Ratio|BLCO (bausch.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Glaukos|Apellis Pharmaceuticals, Inc. - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio BLTE|HROW (Harrow Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio VRDN (Viridian Therapeutics)|Market Capitalization to Book Value Ratio lenz-tx.com LENZ|OCS - Market Value to Book Value Ratio|Market Value to Book Value EYPT (EyePoint Pharmaceuticals Inc)|Kodiak Pharma (KOD) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Aldeyra Therapeutics, Inc.|KALA (KALA BIO Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Opus Bio|Market Cap to Net Assets Ratio OKYO (OKYO Pharma Limited)|ADVM (adverum.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio OTLK (Outlook Pharma)|Clearside Corp (CLSD) - Market-to-Book Ratio|NBY: Market Cap to Net Assets Ratio|Market-to-Book Ratio Kiora Pharmaceuticals|ALIM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Eyenovia (EYEN)|Market Value to Book Value Ratio Guardion Health Sciences Inc.|Ocuphire Corporation (OCUP) - Market Capitalization to Book Value|Market Value to Book Value Ratio Opthea Limited (OPT)